KYVERNA THERAPEUTICS, INC. COMMON STOCK
NASDAQ: KYTX (Kyverna Therapeutics, Inc.)
Kemas kini terakhir: 2 hari lalu, 10:15PM8.21
0.09 (1.11%)
| Penutupan Terdahulu | 8.12 |
| Buka | 8.00 |
| Jumlah Dagangan | 433,473 |
| Purata Dagangan (3B) | 1,485,936 |
| Modal Pasaran | 489,370,208 |
| Harga / Buku (P/B) | 2.85 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 26 Mar 2026 |
| EPS Cair (TTM) | -3.24 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 3.10% |
| Nisbah Semasa (MRQ) | 7.44 |
| Aliran Tunai Operasi (OCF TTM) | -133.64 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -80.19 M |
| Pulangan Atas Aset (ROA TTM) | -31.08% |
| Pulangan Atas Ekuiti (ROE TTM) | -49.72% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | Kyverna Therapeutics, Inc. | Menaik | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | 3.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -4.5 |
| Purata Bergerak Teknikal | -2.5 |
| Osilator Teknikal | -2.0 |
| Purata | -1.50 |
|
Kyverna Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing cell therapies for patients suffering from autoimmune diseases. Its product, KYV-101, is an autologous CD19 CAR T-cell product candidate made from an underlying chimeric antigen receptor, or CAR. It is also developing KYV-201, an allogeneic therapy containing the same CAR as KYV-101, to develop it in multiple autoimmune diseases. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| % Dimiliki oleh Orang Dalam | 12.04% |
| % Dimiliki oleh Institusi | 68.57% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Vida Ventures Advisors, Llc | 30 Sep 2025 | 4,523,924 |
| Gordonmd Global Investments Lp | 31 Dec 2025 | 4,391,818 |
| Insight Holdings Group, Llc | 31 Dec 2025 | 989,054 |
| Propel Bio Management, Llc | 31 Dec 2025 | 666,666 |
| Mbb Public Markets I Llc | 31 Dec 2025 | 614,477 |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 33.00 (Wells Fargo, 301.95%) | Beli |
| Median | 29.00 (253.23%) | |
| Rendah | 25.00 (Morgan Stanley, 204.51%) | Beli |
| Purata | 29.00 (253.23%) | |
| Jumlah | 2 Beli | |
| Harga Purata @ Panggilan | 9.04 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Wells Fargo | 16 Dec 2025 | 33.00 (301.95%) | Beli | 10.24 |
| Morgan Stanley | 04 Dec 2025 | 25.00 (204.51%) | Beli | 7.84 |
Tiada data dalam julat masa ini.
| Tarikh | Jenis | Butiran |
|---|---|---|
| 03 Feb 2026 | Pengumuman | Kyverna Therapeutics Appoints Mayo Pujols as Chief Technology Officer |
| 12 Jan 2026 | Pengumuman | Kyverna Therapeutics Provides Corporate Update and Outlines 2026 Strategic Priorities at the J.P. Morgan Healthcare Conference |
| 05 Jan 2026 | Pengumuman | Kyverna Therapeutics to Present at the J.P. Morgan 2026 Healthcare Conference |
| 17 Dec 2025 | Pengumuman | Kyverna Therapeutics Announces Pricing of $100 Million Public Offering of Common Stock |
| 15 Dec 2025 | Pengumuman | Kyverna Therapeutics Announces Proposed Public Offering of Common Stock |
| 15 Dec 2025 | Pengumuman | Kyverna Therapeutics Announces Positive Topline Data from Registrational KYSA-8 Trial of Miv-cel (KYV-101) in Stiff Person Syndrome |
| 14 Dec 2025 | Pengumuman | Kyverna Therapeutics to Report Topline Results from Registrational Phase 2 KYSA-8 Trial of KYV-101 in Stiff Person Syndrome |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |